Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Unbiased Proteomics Method to Assess the Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Cai W, Zhang J, De Lange WJ, Gregorich ZR, Karp H, Farrell ET, Mitchell ST, Tucholski T, Lin Z, Biermann M, McIlwain S, Ralphe JC, Kamp TJ, Ge Y.

Circ Res. 2019 Oct 1. doi: 10.1161/CIRCRESAHA.119.315305. [Epub ahead of print]

PMID:
31573406
2.

Treatment of MDR-TB using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsules.

Bolhuis MS, van der Werf TS, Kerstjens HAM, de Lange WCM, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Aug 22. pii: 1900580. doi: 10.1183/13993003.00580-2019. [Epub ahead of print] No abstract available.

PMID:
31439686
3.

Impact of radiographic screening of >34 000 asylum seeker children.

Wolters BA, Akkerman OW, Aartsma Y, de Lange WCM, Schölvinck EH, van der Werf TS, van Hest R.

Eur Respir J. 2019 Oct 1;54(3). pii: 1900579. doi: 10.1183/13993003.00579-2019. Print 2019 Sep. No abstract available.

PMID:
31109988
4.

Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.

Dekkers BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, van der Werf TS, Alffenaar JC, Akkerman OW.

Eur Respir J. 2019 Sep 5;54(3). pii: 1900373. doi: 10.1183/13993003.00373-2019. Print 2019 Sep. No abstract available.

PMID:
31048350
5.

Advective Transport Phenomena to Better Understand Dispersion in Field and Modeling Practice.

de Lange WJ.

Ground Water. 2019 Mar 20. doi: 10.1111/gwat.12883. [Epub ahead of print]

PMID:
30891733
6.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10.1097/FTD.0000000000000597. No abstract available.

PMID:
30883521
7.

Novel Adult-Onset Systolic Cardiomyopathy Due to MYH7 E848G Mutation in Patient-Derived Induced Pluripotent Stem Cells.

Yang KC, Breitbart A, De Lange WJ, Hofsteen P, Futakuchi-Tsuchida A, Xu J, Schopf C, Razumova MV, Jiao A, Boucek R, Pabon L, Reinecke H, Kim DH, Ralphe JC, Regnier M, Murry CE.

JACC Basic Transl Sci. 2018 Dec 31;3(6):728-740. doi: 10.1016/j.jacbts.2018.08.008. eCollection 2018 Dec.

8.

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.

9.

Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling.

Farrell E, Armstrong AE, Grimes AC, Naya FJ, de Lange WJ, Ralphe JC.

Front Physiol. 2018 Oct 25;9:1442. doi: 10.3389/fphys.2018.01442. eCollection 2018.

10.

A framework for selecting crops for irrigation using mining contaminated water: An example from the Olifants basin of South Africa.

Musvoto C, de Lange WJ.

J Environ Manage. 2019 Feb 1;231:49-58. doi: 10.1016/j.jenvman.2018.09.058. Epub 2018 Oct 13.

PMID:
30326338
11.

[Tuberculosis: from compulsory admission to compulsory treatment].

Drijver-Messelink MT, Kerstjens HAM, de Lange WCM, de Vries J, van der Werf TS, Akkerman OW.

Ned Tijdschr Geneeskd. 2018 Aug 3;162. pii: D2439. Dutch.

PMID:
30182637
12.

A Method to Create a Horizontal Resistance Layer by Injection of a Viscous Fluid: PLAID.

de Lange WJ, Vink JPM.

Ground Water. 2018 Jul;56(4):541-546. doi: 10.1111/gwat.12667. Epub 2018 May 8.

PMID:
29603195
13.

Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries.

Günther G, van Leth F, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Magis-Escurra C, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, Lange C; for TBNET.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):379-386. doi: 10.1164/rccm.201710-2141OC.

PMID:
29509468
14.

The HCM-linked W792R mutation in cardiac myosin-binding protein C reduces C6 FnIII domain stability.

Smelter DF, de Lange WJ, Cai W, Ge Y, Ralphe JC.

Am J Physiol Heart Circ Physiol. 2018 Jun 1;314(6):H1179-H1191. doi: 10.1152/ajpheart.00686.2017. Epub 2018 Feb 16.

15.

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May.

16.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

17.

In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar.

18.

Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis.

Ravensbergen SJ, Louka C, Lokate M, Bathoorn E, Pournaras S, van der Werf TS, de Lange WCM, Stienstra Y, Akkerman OW.

Am J Trop Med Hyg. 2018 Feb;98(2):376-378. doi: 10.4269/ajtmh.17-0544. Epub 2017 Dec 21.

19.

Towards a rapid assessment protocol for identifying pit lakes worthy of restoration.

de Lange WJ, Genthe B, Hill L, Oberholster PJ.

J Environ Manage. 2018 Jan 15;206:949-961. doi: 10.1016/j.jenvman.2017.11.084. Epub 2017 Dec 7.

PMID:
29223105
20.

Linking metabolic and contractile dysfunction in aged cardiac myocytes.

Barton GP, de Lange WJ, Ralphe JC, Aiken J, Diffee G.

Physiol Rep. 2017 Nov;5(20). pii: e13485. doi: 10.14814/phy2.13485. Epub 2017 Oct 29.

21.

Increased Postnatal Cardiac Hyperplasia Precedes Cardiomyocyte Hypertrophy in a Model of Hypertrophic Cardiomyopathy.

Farrell ET, Grimes AC, de Lange WJ, Armstrong AE, Ralphe JC.

Front Physiol. 2017 Jun 14;8:414. doi: 10.3389/fphys.2017.00414. eCollection 2017.

22.

Treatment outcomes of MDR-TB and HIV co-infection in Europe.

Magis-Escurra C, Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Davilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBnet.

Eur Respir J. 2017 Jun 8;49(6). pii: 1602363. doi: 10.1183/13993003.02363-2016. Print 2017 Jun. No abstract available.

23.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
24.

Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.

Van Kampenhout E, Bolhuis MS, Alffenaar JC, Oswald LM, Kerstjens HA, de Lange WC, van der Werf TS, Akkerman OW.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601724. doi: 10.1183/13993003.01724-2016. Print 2017 Mar. No abstract available.

25.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

26.

Neurological and functional recovery in tuberculosis patients with spinal cord injury in The Netherlands.

Wouda EMN, Stienstra Y, van der Werf TS, Kerstjens H, de Lange WCM, Coppes M, Kuijlen J, Tepper M, Akkerman OW.

NeuroRehabilitation. 2017;40(3):439-445. doi: 10.3233/NRE-161431.

PMID:
28222564
27.

Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01783-16. doi: 10.1128/AAC.01783-16. Print 2017 Apr.

28.

Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring.

Bolhuis MS, Akkerman OW, Sturkenboom MG, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S44-S45. doi: 10.1016/j.ijmyco.2016.07.003. Epub 2016 Aug 8.

29.

Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes.

Kriegel AJ, Gartz M, Afzal MZ, de Lange WJ, Ralphe JC, Strande JL.

J Cardiovasc Transl Res. 2017 Jun;10(3):295-304. doi: 10.1007/s12265-016-9723-z. Epub 2016 Dec 28. Review.

30.

Positive predictive value of ELISpot in BAL and pleural fluid from patients with suspected pulmonary tuberculosis.

Hofland RW, Thijsen SF, van Lindert AS, de Lange WC, van Gorkom T, van der Tweel I, Lammers JJ, Bossink AW.

Infect Dis (Lond). 2017 May;49(5):347-355. doi: 10.1080/23744235.2016.1269190. Epub 2016 Dec 26.

PMID:
28024452
31.

Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.

Sturkenboom MG, Bolhuis MS, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1695-1696. No abstract available.

PMID:
27931348
32.

Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.

van Altena R, Akkerman OW, Alffenaar JC, Kerstjens HA, Magis-Escurra C, Boeree MJ, van Soolingen D, de Lange WC, Bolhuis MS, Hoefsloot W, de Vries G, van der Werf TS.

Eur Respir J. 2016 Dec;48(6):1800-1802. doi: 10.1183/13993003.01208-2016. Epub 2016 Oct 6. No abstract available.

33.

Treatment Outcomes in Multidrug-Resistant Tuberculosis.

Günther G, Lange C, Alexandru S, Altet N, Avsar K, Bang D, Barbuta R, Bothamley G, Ciobanu A, Crudu V, Danilovits M, Dedicoat M, Duarte R, Gualano G, Kunst H, de Lange W, Leimane V, Magis-Escurra C, McLaughlin AM, Muylle I, Polcová V, Popa C, Rumetshofer R, Skrahina A, Solodovnikova V, Spinu V, Tiberi S, Viiklepp P, van Leth F; for TBNET.

N Engl J Med. 2016 Sep 15;375(11):1103-5. doi: 10.1056/NEJMc1603274. No abstract available.

34.

Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.

Sturkenboom MG, Akkerman OW, van Altena R, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JC.

Eur Respir J. 2016 Oct;48(4):1237-1239. doi: 10.1183/13993003.00986-2016. Epub 2016 Aug 4. No abstract available.

35.

Pharmacokinetic/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB.

Ghimire S, Van't Boveneind-Vrubleuskaya N, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Wilffert B, Touw DJ, Alffenaar JW.

J Antimicrob Chemother. 2016 Oct;71(10):2691-703. doi: 10.1093/jac/dkw164. Epub 2016 May 26. Review.

PMID:
27231277
36.

Towards tradable permits for filamentous green algae pollution.

de Lange WJ, Botha AM, Oberholster PJ.

J Environ Manage. 2016 Sep 1;179:21-30. doi: 10.1016/j.jenvman.2016.04.052. Epub 2016 May 4.

PMID:
27155255
37.

High Prevalence of Infectious Diseases and Drug-Resistant Microorganisms in Asylum Seekers Admitted to Hospital; No Carbapenemase Producing Enterobacteriaceae until September 2015.

Ravensbergen SJ, Lokate M, Cornish D, Kloeze E, Ott A, Friedrich AW, van Hest R, Akkerman OW, de Lange WC, van der Werf TS, Bathoorn E, Stienstra Y.

PLoS One. 2016 May 4;11(5):e0154791. doi: 10.1371/journal.pone.0154791. eCollection 2016.

38.

Cotranslational association of mRNA encoding subunits of heteromeric ion channels.

Liu F, Jones DK, de Lange WJ, Robertson GA.

Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4859-64. doi: 10.1073/pnas.1521577113. Epub 2016 Apr 12.

39.

Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.

Alsaad N, Dijkstra JA, Akkerman OW, de Lange WC, van Soolingen D, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3942-7. doi: 10.1128/AAC.02175-15. Print 2016 Jul.

40.

Implementing tuberculosis entry screening for asylum seekers: the Groningen experience.

Akkerman OW, de Lange WC, Schölvinck EH, Wolters B, Aartsma Y, van der Werf TS, van Hest R.

Eur Respir J. 2016 Jul;48(1):261-4. doi: 10.1183/13993003.00112-2016. Epub 2016 Mar 23. No abstract available.

41.

Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics.

Ghimire S, Bolhuis MS, Sturkenboom MG, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Jun;47(6):1867-9. doi: 10.1183/13993003.00040-2016. Epub 2016 Mar 17. No abstract available.

42.

Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis.

Zuur MA, Bolhuis MS, Anthony R, den Hertog A, van der Laan T, Wilffert B, de Lange W, van Soolingen D, Alffenaar JW.

Expert Opin Drug Metab Toxicol. 2016 May;12(5):509-21. doi: 10.1517/17425255.2016.1162785. Epub 2016 Mar 24. Review.

PMID:
26950189
43.

End TB with precision treatment!

van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, Cobelens FG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Feb;47(2):680-2. doi: 10.1183/13993003.01285-2015. No abstract available.

44.

Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis.

Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang CY, Keshavjee S, Koh WJ, Shiraishi Y, Viiklepp P, Yim JJ, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Ahuja S, Ashkin D, Avendaño M, Banerjee R, Bauer M, Burgos M, Centis R, Cobelens F, Cox H, D'Ambrosio L, de Lange WCM, DeRiemer K, Enarson D, Falzon D, Flanagan K, Flood J, Gandhi N, Garcia-Garcia L, Granich RM, Hollm-Delgado MG, Holtz TH, Hopewell P, Iseman M, Jarlsberg LG, Kim HR, Lancaster J, Lange C, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Narita M, Nathanson E, Odendaal R, O'Riordan P, Pai M, Palmero D, Park SK, Pena J, Pérez-Guzmán C, Ponce-de-Leon A, Quelapio MID, Quy HT, Riekstina V, Royce S, Salim M, Schaaf HS, Seung KJ, Shah L, Shean K, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Sung SW, Tabarsi P, Tupasi TE, Vargas MH, van Altena R, van der Walt M, van der Werf TS, Westenhouse J, Yew WW.

Clin Infect Dis. 2016 Apr 1;62(7):887-895. doi: 10.1093/cid/ciw002. Epub 2016 Jan 12.

PMID:
26757804
45.

Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae.

Gröschel MI, Omansen TF, de Lange W, van der Werf TS, Lokate M, Bathoorn E, Akkerman OW, Stienstra Y.

Am J Trop Med Hyg. 2016 Mar;94(3):517-8. doi: 10.4269/ajtmh.15-0690. Epub 2016 Jan 11.

46.

Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.

van Rijn SP, van Altena R, Akkerman OW, van Soolingen D, van der Laan T, de Lange WC, Kosterink JG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Apr;47(4):1229-34. doi: 10.1183/13993003.01654-2015. Epub 2016 Jan 7.

47.

Pharmacokinetics of Bedaquiline in Cerebrospinal Fluid and Serum in Multidrug-Resistant Tuberculous Meningitis.

Akkerman OW, Odish OF, Bolhuis MS, de Lange WC, Kremer HP, Luijckx GJ, van der Werf TS, Alffenaar JW.

Clin Infect Dis. 2016 Feb 15;62(4):523-4. doi: 10.1093/cid/civ921. Epub 2015 Nov 3. No abstract available.

PMID:
26534926
48.

Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis.

Dijkstra JA, van Altena R, Akkerman OW, de Lange WC, Proost JH, van der Werf TS, Kosterink JG, Alffenaar JW.

Int J Antimicrob Agents. 2015 Sep;46(3):332-7. doi: 10.1016/j.ijantimicag.2015.06.008. Epub 2015 Jul 15.

PMID:
26228464
49.

Determination of bedaquiline in human serum using liquid chromatography-tandem mass spectrometry.

Alffenaar JW, Bolhuis M, van Hateren K, Sturkenboom M, Akkerman O, de Lange W, Greijdanus B, van der Werf T, Touw D.

Antimicrob Agents Chemother. 2015 Sep;59(9):5675-80. doi: 10.1128/AAC.00276-15. Epub 2015 Jul 6.

50.

[A sore throat: tumour, tuberculosis or both?].

van der Sar-van der Brugge S, Akkerman OW, van der Laan BF, de Lange WC, van der Werf TS.

Ned Tijdschr Geneeskd. 2015;159:A8942. Review. Dutch.

PMID:
26104006

Supplemental Content

Loading ...
Support Center